secwatch.observer — SEC 8-K summary
======================================

Issuer:     TuHURA Biosciences, Inc./NV (HURA)
CIK:        0001498382
Form:       8-K
Filed at:   2024-10-21T23:59:59+00:00
Accession:  0000950170-24-115765
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 2.01, 1.01, 9.01, 5.02, 2.02, 3.03, 5.01, 5.03, 5.06, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Kintara completes reverse merger with TuHURA; renamed TuHURA Biosciences, trades as HURA
--------------------------------------------------------------------------------

- Merger closed Oct 18, 2024; Kintara securityholders own ~2.85% of combined entity (or 5.45% if CVR milestone met).
- TuHURA securityholders own ~97.15% (or 94.55% after CVR shares).
- 1-for-35 reverse stock split pre-merger; common stock now trades under HURA on Nasdaq.
- CVRs issued to former Kintara holders; up to ~1.54M shares payable if REM-001 CMBC study milestone met by Dec 31, 2025.
- Combined company focuses on TuHURA's personalized cancer vaccine IFx-2.0; Phase 3 trial in MCC planned for Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1498382/000095017024115765/0000950170-24-115765-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1498382/000095017024115765/hura-20241018.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-115765

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer